![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
May 28, 2026
Dr. Anagnostou is honored as a world-renowned lung cancer translational research investigator
May 28, 2026
The group is recognizing Dr. Berlin for his sustained commitment to mentoring early- and mid-career investigators in cancer medicine
May 28, 2026
ACHIEVE is the first lung cancer clinical trial for older patients with metastatic NSCLC, comparing immunotherapy (pembrolizumab) with and without chemotherapy
May 28, 2026
Timely information about research presented at medical meetings, recognition of research leaders, and more
May 20, 2026
This phase 3 clinical trial is comparing aromatase inhibitors and ribociclib, with and without chemotherapy, to prevent recurrence
April 24, 2026
This phase 2 trial is evaluating pembrolizumab immunotherapy after surgery in patients with recurrent or second primary head and neck cancer with high-risk features
April 24, 2026
Timely information about research presented at medical meetings, recognition of research leaders, and more
March 30, 2026
This phase 3 clinical trial is evaluating a less intensive treatment approach for adults aged 75+ with early-stage melanoma
March 30, 2026
This phase 3 trial seeks to determine if there is any survival benefit from adding a fourth drug to induction therapy—and if so, in which patients
March 30, 2026
These studies aim to improve patient outcomes and well-being by examining complex interactions between patients, providers, and care delivery systems
March 30, 2026
The latest findings in breast cancer, cancer care delivery research, head and neck cancer, leukemia, and radiation therapy
March 30, 2026
Timely information about research presented at medical meetings, recognition of research leaders, and more